Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 84, Issue 3, 2009, Pages 188-190

  Gesundheit, Benjamin ^a   Shapira, Michael Y ^a   Resnick, Igor B ^a   Amar, Avraham ^a   Kristt, Don ^b   Dray, Lilianne ^a   Budowski, Einat ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CELL MEDIATED CYTOKINE ACTIVATED IMMUNOTHERAPY; CHILD; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

CHILD; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 62949174395     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21346     Document Type: Article

References (20)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
2. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-2042.
3. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clinic Proc 2006;81:247-260.
4. Béhar C, Suciu S, Benoit Y, et al. Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: Results of the EORTC Children Leukemia Cooperative Study 58872. Med Pediatr Oncol 1996;26:173-179.
5. Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 2007;13:1-25.
6. Drobyski WR. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004;18:1565-1568.
7. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
8. Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007;56:943-957.
9. Porter DL, Antin JH. Donor leukocyte infusions in myeloid malignancies: New strategies. Best Pract Res Clin Haematol 2006;19:737-755.
10. Buggins AG, Milojkovic D, Arno MJ, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 2001;167:6021-6030.
11. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
12. Slavin S, Morecki S, Weiss L, et al. Nonmyeloablative stem cell transplantation: Reduced-intensity conditioning for cancer immunotherapy - From bench to patient bedside. Semin Oncol 2004;31:4-21.
13. Steegmann JL, Casado LF, Tomas JF, et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:483-488.
14. Benjamin R, Khwaja A, Singh N, et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 2007;109:1244-1247.
15. Gesundheit B, Shapira MY, Maly A, et al. Induction of late graft-versus-host disease in a patient post-allogeneic stem cell transplantation by progesterone in conjunction with donor lymphocyte infusion. Leuk Res 2008;32:501-503.
16. Hartwig M, Weigel S, Bernig T, et al. Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2007;24:137-140.
17. Vettenranta K, Hovi L, Saarinen-Pihkala UM. Adoptive immunotherapy as consolidation of remission in pediatric AML relapsing post-transplant. Pediatr Transplant 2003;7:446-449.
18. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004;33:815-821.
19. Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: Technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant 2007;39:255-268.
20. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.